

Creating Successful Service Models

Mark Sales, Global Practice Leader, Stakeholder Management

harmaceutical companies have begun a dramatic transition from product-centric sales models to physician-centric service models. More than 90% of company executives now say they are adopting service models, expanding their focus from measuring internal sales processes to motivating external sales drivers: the physicians writing prescriptions and the stakeholders influencing them.

To understand this shift, consider that, of every 100 reps visiting a practice, just 20 see the doctor. Clearly, just throwing more reps into the field isn't the answer to generating business.

Add to that today's dwindling pipelines and tightening revenue squeeze, and it's easy to see why companies are radically rethinking where they spend promotional dollars. It's no longer enough for reps to deliver sales messages. To have an impact, they must coordinate value —providing a range of services to doctors.

To understand service models from physicians' perspectives, TNS Healthcare, performed new research with 1,500-plus primary care physicians across the United States, the United Kingdom, France, Germany, Italy, and Spain. Following are some key findings:

1. Fewer Doctors Perceive Changes from the Move to Service Models

In 2009, only one-third of doctors report seeing changes in their interactions with pharma, due to the new service models. This represents a decline from 2008, when almost half of physicians said they were experiencing changes. The decrease holds true across all countries and is particularly dramatic in Spain and Germany.

2. Physicians Value the Sales Force But Also Place High Importance on Education and Practice Support

In all countries, physicians place the greatest value on sales force attributes, including reps' conduct, knowledge, and expertise, as well as call quality. Even though reps remain critically important, other experiences are gaining in value, particularly physician education, practice support and patient services. For example, more than three-quarters of doctors place a high value on physician education.

3. Falling Rep Relationship Scores Reveal Challenges across the US and Europe

In the United States, four companies share the lead, based on their reps' ability to build strong physician relationships —GlaxoSmithKline, Merck, Novartis, and Pfizer. Even for companies earning high marks, however, TRI*M™ scores —TNS's measure of relationship strength — have fallen since 2008. In the United States, TRI*M scores fell from 78

to 75. Relationship scores also fell in Germany. Scores in France and the United Kingdom remain low, showing continuing challenges in those countries. Spain bucks the trend, as the only country showing a significant jump in its TRI*M score.

4. Novartis Takes the Lead on Service Delivery in Europe, While Merck Takes Top Honors in the United States.

In addition to assessing relationship strength, the survey asked doctors to rate 17 companies from 1 to 5 (with 1 being poor and 5 excellent) on a range of experiences: rep conduct; rep knowledge and expertise; sales visit quality; patient management, education and support; physician education; practice and staff support; Web services for doctors; Web services for patients; brand experience; and corporate reputation.

In the United States, Merck is the leader with first-place scores in all service categories. GSK and Pfizer ties for second place, and Novartis and Lilly for third. In Europe, four out of five countries — the United Kingdom, Germany, Spain, and Italy — give Novartis top marks. Sanofi-Aventis takes the top spot in France and ties for first place in the United Kingdom and Germany.

5. Pharma Faces Negative Word of Mouth (WOM) around the World

TRI*M identifies four customer segments:

- Apostles: Customers who are satisfied and actively generating positive WOM.
- Rebels: Customers who are dissatisfied and actively generating negative WOM.
- Hostages: Customers who don't want to stay with a company but feel they have no other choices.
- Mercenaries: Customers with low loyalty who will move on quickly to what they see as the next "best deal."

TRI*M reveals a new and unsettling trend in the United States. The percent of U.S. doctors now classified as "rebels" has risen sharply in the last year, from 12% to 19%. For the first time, U.S. companies face a negative market environment. All five major European markets have traditionally had a high proportion of rebels and that trend continues in 2009.

Conclusion

Although many companies receive high ratings for their service experiences, increasingly negative word of mouth and declining relationship scores show there is still improvement needed. Successful companies will be those that remember service models, first and foremost, are about strengthening relationships.

SPONSOR: TNS HEALTHCARE, a Kantar Health company, provides globally consistent solutions and custom advisory services to support product introductions; brand, treatment, and sales-performance optimization; and professional and DTC promotional tracking. For more information, visit tnsglobal.com/healthcare.



Your Brand May Look Like It's Sailing Along. But Could Your Sales Be Heading for a Major Fall?



NEW Sales Performance Optimization[™] Reveals the Unseen Risks for Your Brand—and the Actions to Keep It Safe (Even When Competitors Try to Make Waves).

Your prescription data may tell you your brand's sales are safe. But are they? In most major classes, up to 50% of high prescribers are ready to switch to a competitor. If you're only looking at Rx information, you'll never see that fall coming—or know how to avoid it.

That's why TNS Healthcare's NEW Sales Performance Optimization (SPO) shows you not only how much doctors write your brand but how committed they are to it. Then, it tells you how to create the ideal sales experience to drive doctors' Commitment, reduce risk and build share. SPO looks at every facet of your physician relationships—from rep interactions to patient communications to practice support to company and brand attributes. You know where to focus your sales efforts—and what you'll gain in return.

Why is Commitment important? Committed physicians deliver more than double the patient share. Resist competitive efforts. And have lower price sensitivity. They're far more productive today—and tomorrow. When your high prescribers are also committed prescribers, you take the risk out of your future. And that means smooth sailing for a long time to come.

> Learn results of new research on what US and EU doctors value and how they rate 17 pharma companies on delivering!

For your FREE copy, email TNSHealthcareInfo@tns-global.com and put "RESULTS" in the subject line.

Make sure you see the perils ahead—and know how to navigate safely around them.

To find out how SPO can optimize your sales effectiveness, contact Wes Michael at 410-559-0291 or Wes.Michael@tns-global.com.